spacer
The Healthcare Sales & Marketing Network celebrates 23 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  pseudobulbar affect 

 HSMN NewsFeed - 9 Jun 2016
NUEDEXTA(R) Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 3 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 14 Aug 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 Jul 2013
BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 16 Mar 2012
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 31 Jan 2011
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Oct 2010
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 May 2010
AVANIR Pharmaceuticals Announces Hiring of Michael McFadden as Vice President of U.S. Sales and Managed Markets
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 Oct 2007
AVANIR Granted Special Protocol Assessment (SPA) From FDA for Confirmatory Phase III Trial of Zenvia in Patients With PBA
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Aug 2007
AVANIR Pharmaceuticals Completes Sale Of FazaClo
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 30 Jan 2007
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Apr 2006
AVANIR Announces Neurodex Phase III Trial Results Published in Annals of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Apr 2006
AVANIR's Neurodex NDA Accepted with Priority Review for Involuntary Emotional Expression Disorder
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Jan 2006
AVANIR Submits Expanded Neurodex New Drug Application for the Treatment of Involuntary Emotional Expression Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2006
AVANIR Licenses Docosanol 10% Cream in Japan
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 11 Jan 2006
AVANIR Pharmaceuticals Hires Randall E. Kaye, M.D. as Vice President of Medical Affairs
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
pseudobulbar affect
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.